Lung Cancer Survival Rate: A Complete Guide by Stage and Age

Few numbers hit as hard as a survival statistic after a lung cancer diagnosis. But what does a figure like 28% really mean — and how much does your stage or age change the outlook? Survival rates are a powerful tool, not a crystal ball. The American Cancer Society puts the overall five-year relative survival for all lung cancers at about 23%, a number that shifts dramatically when you break it down by stage and cell type. This guide walks through the most current data on lung cancer survival rates, separating hope from hype so you can talk with your oncologist with confidence.

Overall 5-year survival (all stages): 28.1% (SEER-based) ·
Stage 1 5-year survival: 65% ·
Stage 4 5-year survival: 21.4% ·
Women 5-year survival: 15.3%

Sourced from American Cancer Society, WebMD, and Cancer Research UK data.

Here’s a quick reference table of key survival statistics from major sources.

What is the life expectancy of lung cancer?

Life expectancy for lung cancer is most often measured by the five-year relative survival rate — the percentage of people who live at least five years after diagnosis compared to the general population. But that single number hides a wide range.

The overall five-year relative survival for all lung cancers combined is about 23% according to the NCI SEER (population-based data). When you break it down by stage, the picture changes completely.

Lung cancer survival rates by stage (NSCLC)

The following table shows the variation in stage-specific survival across three major health organizations.

Cancer Research UK (U.K. cancer registry) reports slightly lower distant-stage survival because their cohort includes older patients. The pattern across sources is consistent: earlier stage equals dramatically better odds.

Stage 4 lung cancer survival rate without treatment

Without any treatment, the prognosis for stage 4 lung cancer is poor — median survival often falls to 4–6 months. Data from WebMD (clinical review) suggests the 5-year survival rate for untreated stage 4 drops to around 10% or less. Modern therapies can extend survival significantly, but the baseline is sobering.

Factors that affect life expectancy

• Cell type (NSCLC vs. SCLC) — SCLC tends to spread faster but responds initially to chemotherapy.
• Age at diagnosis — older patients generally have more comorbidities and lower survival.
• Overall health (performance status) — people with good functional status live longer on average.
• Access to targeted therapy and immunotherapy — these can double survival for certain mutations.

The pattern is clear: stage trumps all other factors, but age and treatment still shift the curve by months to years.

The implication: knowing your stage is the single most powerful predictor of your outlook.

Can lung cancer be cured?

Yes — but mostly when caught early. The word “cure” is used cautiously in oncology, but for localized lung cancer, treatment can achieve long-term remission.

Cure rates for early-stage lung cancer

For stage 1 non-small cell lung cancer, surgical removal of the tumor yields a 5-year survival of about 65–67%. Many of those patients remain cancer-free. The National Cancer Institute (PDQ treatment summary) describes surgery as potentially curative for stage 1 NSCLC.

Treatment options that can lead to remission

• Surgery: lobectomy or segmentectomy for early-stage tumors.
• Radiation: stereotactic body radiation (SBRT) for patients who cannot tolerate surgery.
• Chemotherapy and immunotherapy: used before or after surgery for higher-risk disease.

For advanced stages, the goal shifts from cure to control. But modern immunotherapy combinations have produced durable responses in some patients with stage 4 disease, a shift acknowledged by the American Cancer Society (treatment guidelines).

When is lung cancer considered incurable?

Once the cancer has spread extensively — to the other lung, the fluid around the lung, or distant organs — cure is rarely achieved. However, palliative chemotherapy, radiation, and immunotherapy can extend life and improve quality of life. The Cancer Research UK (treatment overview) emphasizes that even incurable lung cancer can be managed as a chronic illness for years in some cases.

What this means: early detection is the single most effective tool for improving cure rates.

What are the silent signs of lung cancer?

Lung cancer is notorious for being diagnosed late because early symptoms are easy to ignore. Knowing the warning signs — both common and subtle — can prompt earlier detection.

Unexpected lung cancer symptoms

• A cough that doesn’t go away or changes over time (most common early sign).
• Shortness of breath or wheezing — often mistaken for asthma or aging.
• Chest pain that is persistent and often worse with deep breathing or coughing.
• Hoarseness or a change in voice from pressure on the recurrent laryngeal nerve.

The CDC (basic symptom guide) lists a persistent cough as the most common presenting symptom. Many people dismiss it as a smoker’s cough or seasonal allergies.

Which symptom is a late manifestation of lung cancer?

Late-stage signs include bone pain (from metastasis), headaches or neurological changes (brain mets), unexplained weight loss, and swelling of the face or neck (superior vena cava syndrome). The EPA (radon health risk page) notes that weight loss and fatigue often signal advanced disease.

How painful is lung cancer?

Pain intensity varies. Many early-stage patients report no pain at all. When pain does appear, it’s often in the chest, shoulder, or back, caused by the tumor pressing on nerves or the chest wall. The National Cancer Institute (patient treatment summary) describes pain management as a key part of palliative care, with medications, radiation, and nerve blocks available.

The pattern: ignoring early signs can turn a curable stage 1 into a stage 4 diagnosis.

What happens after a lung cancer diagnosis?

The days and weeks after diagnosis can feel overwhelming. Knowing what comes next — from staging tests to treatment planning — helps reduce anxiety and empowers you to ask informed questions.

What do they do when you have lung cancer?

The first step is staging: determining how far the cancer has spread. This typically involves a CT scan, PET scan, and a biopsy (bronchoscopy, needle, or surgical). The National Cancer Institute (treatment summary) explains that staging guides all treatment decisions.

What is the 2 week rule for lung cancer?

In the U.K., the “2-week rule” means that if a GP suspects lung cancer (based on chest X-ray findings or persistent symptoms), a specialist appointment must happen within two weeks. While this rule is specific to the NHS (lung cancer referral guidelines), similar urgent referral pathways exist in many countries. The goal is to accelerate diagnosis and improve early-stage detection.

Treatment options and next steps

Treatment options vary by stage as summarized below.

The American Cancer Society (treatment by stage) provides a detailed breakdown. The pattern: early stage = surgery; late stage = systemic therapy with targeted or immune agents.

How serious is lung cancer?

Lung cancer is the third most common cancer in the United States — after breast and prostate — but it kills more people than any other cancer: about 125,000 deaths per year according to the CDC (basic cancer data). The seriousness depends largely on stage at diagnosis, but even advanced disease now has treatment options that weren’t available a decade ago.

Stage 3 lung cancer survival rate

Stage 3 NSCLC (regional spread) carries a 5-year survival of about 32.6% in combined U.S. data, according to the WebMD (SEER analysis). With modern chemoradiation and immunotherapy, some stage 3 patients achieve long-term remission.

Stage 2 lung cancer survival rate

For stage 2 NSCLC, the 5-year survival is approximately 56.1% based on SEER data. The Cancer Research UK (stage-specific survival) reports a similar figure of around 40–50% depending on exact substage (IIA vs IIB).

Survival rates by age

Older age is associated with lower survival across all stages. The National Cancer Institute SEER data shows that the median age at diagnosis is 70, and patients over 75 have significantly worse outcomes, partly due to comorbidities and less aggressive treatment.

The catch: even with advanced disease, modern therapies are transforming outcomes for some patients.

Survival rate comparison across major sources

Five sets of data, one consistent pattern: survival drops with stage, but exact numbers vary by source due to different populations and cutoffs. Here’s how the leading authorities compare:

The WebMD staging table shows that even within the same broad SEER category, specific T,N,M factors can dramatically change the odds — a IIB tumor (T3) has 56% survival, while a IIIB (T4) falls to 24%.

Lung cancer survival is not a single number — it’s a spectrum that shifts with stage, type, age, and access to care. For someone newly diagnosed, the most important step is understanding their specific stage and cell type, then talking to an oncologist about the best treatment pathway. For patients in the U.S., the CDC emphasizes that early detection through screening (low-dose CT) is the single most impactful way to improve survival. For those already facing a later stage, modern immunotherapy can turn months into years. The choice: know your numbers, ask about clinical trials, and never assume the population average applies to you.

Frequently asked questions

Related reading

• Complex Regional Pain Syndrome: Symptoms, Causes & Treatment — Explore another chronic condition affecting millions.
• Symptoms of a Stroke: 5 Warning Signs and FAST Test — Learn to recognize stroke symptoms fast.